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Abstract
The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be
an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with
measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome.
142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-
smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-a and HB-EGF) showed significant
differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the
COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV1, FEV1/FVC and
DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in
DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of
expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster
associated with FEV1 related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-a) formed another cluster
associated with both DLCO and FEV1 related parameters. Associations of Fibrinogen with DLCO and MPO with FEV1/FVC
were stronger in patients without metabolic syndrome (r = 20.52, p =0.005 and r = 20.61, p =0.023, respectively)
compared to patients with coexisting metabolic syndrome (r = 20.25, p =0.47 and r=20.15, p =0.96, respectively), and
may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum
protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV1, FEV1/FVC and DLCO.
These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as
key pathways associated with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a heteroge-
neous condition variably characterized by progressive airflow
limitation with dyspnea, airway inflammation and remodeling,
lung parenchymal destruction with emphysema, systemic inflam-
mation and comorbidities including cardiovascular disease and
metabolic syndrome [1,2]. Currently, there are limited therapies to
prevent disease progression, effectively treat inflammation or
reduce mortality, and the development of novel treatment
strategies will require a deeper understanding of the underlying
inflammatory and tissue injury/repair processes associated with
COPD disease pathogenesis [3]. Moreover, while therapeutic
trials have largely relied on FEV1 as a primary endpoint and the
central measure of disease severity, FEV1 remains a poor surrogate
for disease activity and for distinguishing COPD sub-phenotypes
[4,5,6]. Thus, there is a need for surrogate biomarkers, including
accessible blood biomarkers, to support COPD patient stratifica-
tion for clinical trials or to serve as predictors of disease
progression, extrapulmonary effects and comorbidities [5,6].
Despite intensive research only a few disease-related markers
have emerged. C-reactive protein (CRP), Fibrinogen and IL-6 are
reported to be related to systemic inflammation [7,8,9,10],
exacerbations and other lung function parameters [11,12] in
COPD. Elevated levels of soluble TNF receptor-1 (sTNFR-1),
Osteoprotegerin and neutrophil gelatinase associated lipocalin
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38629(NGAL) were associated with GOLD stage and frequency of
exacerbation in the Bergen COPD cohort [13,14], and myelo-
peroxidase (MPO) and vascular endothelial growth factor (VEGF)
were associated with the severity of lung function impairment and
dyspnea in a separate study [15]. Several studies, including those
analyzing the ECLIPSE COPD cohort [16,17,18,19,20], have
identified decreased circulating levels of the Clara cell protein CC-
16 in patients with COPD, suggesting that this protein may be a
marker of potential interest in predicting bronchial epithelial cell
dysfunction. In a multiplex profiling study, Pinto-Plata et al. [8]
identified a panel of 24 biomarkers in 48 patients with COPD that
showed associations with FEV1 and the BODE index, including
proteins associated with inflammation, chemoattraction and tissue
destruction.
The Grosshansdorf COPD cohort has been instrumental in
defining novel associations between systemic inflammation and
extrapulmonary comorbidities such as metabolic syndrome
[21,22,23,24,25,26,27]. In the current study, we extended our
assessment of this cohort by performing a cross-sectional analysis
of 142 systemic biomarkers in COPD patients, smokers without
COPD and healthy non-smoking controls. In selecting the protein
analytes to be interrogated in this study we focused first on known
biomarkers in COPD, and expanded this panel to include a wider
array of protein analytes associated with biological pathways
hypothesized to play a role in COPD disease pathogenesis,
including inflammation and chemokine signaling, growth factor/
tissue repair pathways and metabolic regulation. We performed
analyses in this study to address three objectives. The first objective
was to identify systemic biomarker changes associated with COPD
disease severity, comparing COPD patients against smoking and
non-smoking control subjects. The second objective was to identify
associations between biomarkers and lung function parameters in
COPD patients using univariate and multivariate regression.
Lastly, metabolic syndrome has been observed to be a frequent
comorbidity in patients with COPD, and previous studies by Watz
et al. [21] found increased levels of IL-6 and hs-CRP in patients
with COPD and coexisting metabolic syndrome compared to
COPD patients without metabolic syndrome. Thus, the third
objective was to determine if biomarkers associated with lung
function parameters differed in COPD patients with or without
coexisting metabolic syndrome. The identified associations may
contribute toward a better overall understanding of COPD
pathogenesis and inform future biomarker studies in COPD.
Results
Clinical Characteristics of Cohort
The Grosshansdorf COPD cohort used in the present study
consisted of a total of 185 subjects including 30 healthy non-
smokers, 15 smoking controls with chronic bronchitis (i.e. GOLD
stage 0 in former GOLD classification scheme, on average 43 pack
years of smoking) and 140 patients with COPD (GOLD stage I-
IV). Of these 140 COPD subjects, 65 had metabolic syndrome.
The baseline characteristics of the 185 subjects, including
demographics, smoking history, steroid use and clinical measure-
ments are summarized in Table 1.
Overview of Study Analysis
We performed three sets of analyses on the biomarker data for
this cohort (Figure 1). In the first analysis (analysis I or group-wise
analysis), protein analyte levels were compared between mild/
moderate COPD, severe/very severe COPD and control subject
groups to identify biomarker differences between COPD and
control subjects. Analysis I was performed on all 185 subjects in
the cohort. In the second analysis (analysis II or regression
analysis), biomarker levels were tested for correlation with lung
function parameters on COPD patients only. To prevent possible
confounding effects of pre-medication, analysis II was restricted to
COPD patients not on theophylline or oral systemic steroids.
Analysis II was thus performed on a smaller subset of 102 COPD
patients. In the third analysis (analysis III), we asked if the
associations of biomarkers with lung function parameters identi-
fied in analysis II were affected by the presence of coexisting
metabolic syndrome. We divided the 102 COPD patients in
analysis II into patients with (n =55) and without (n =47)
metabolic syndrome and performed univariate correlation analysis
in each patient subpopulation.
Analysis I: Group-wise Analysis
Seven protein analytes showed significant differences across
COPD disease severity groups (Table 2, Figure 2A and B, analysis
details shown in Figure S1). Subjects were grouped as mild/
moderate COPD (GOLD I, II, n= 75), severe/very severe COPD
(GOLD III, IV, n =65), non-smoking (n= 30) and smoking (n
=15) controls. Extracellular newly identified RAGE-binding
protein (EN-RAGE; also known as S100A12), NGAL, Fibrinogen,
transforming growth factor alpha (TGF-a), heparin-binding EGF-
like growth factor (HB-EGF) and MPO were increased in COPD
patients compared to controls, while soluble receptor for advanced
glycation end products (sRAGE) was decreased in COPD patients.
Only sRAGE and EN-RAGE displayed maximum pairwise fold-
change differences in serum concentration greater than 1.5 fold;
sRAGE decreased by 1.6-fold in severe/very severe COPD
subjects compared to smoking controls, while EN-RAGE
increased by 1.6-fold in subjects with severe/very severe COPD
compared to mild/moderate COPD (Table S2). The trend for
modest fold changes (,2 fold) persisted when analytes were
compared across patients grouped by FEV1 quartile (Table S3).
To confirm that these differences were not due to smoking status,
we compared serum EN-RAGE and sRAGE levels in former and
current smokers across the smoker, mild/moderate COPD and
severe/very severe COPD groups and saw no differences in the
levels of these analytes between these 2 groups (Figure 2C and D,
p =0.52 for sRAGE, p =0.98 for EN-RAGE).
Since the disease severity groups were unbalanced in terms of
sample size, a post-hoc power analysis was also performed to assess
the potential impact on statistical significance of the group-wise
comparison results. The reduced number of subjects in the
smoking control group affected the power to detect analytes with
modest or weak effect sizes, especially after p value correction for
multiple testing. EN-RAGE and NGAL, which displayed strong
effect sizes (.0.25), were powered .0.6 at the a =0.0005 level, a
stricter p value imposed by Bonferroni correction for multiple
testing (Table S4).
Analysis II: Regression Analysis in COPD Patients Only
Univariate regression was performed for each analyte against
FEV1%predicted, FEV1/FVC or DLCO %predicted using data
from 102 COPD subjects only (see Figure 1). COPD patients on
theophylline and/or oral systemic steroids were excluded to avoid
potential confounding effects of pre-medication. Four analytes
were identified as significantly correlated with FEV1 including HB-
EGF, EN-RAGE, TGF-a and MPO; 2 analytes with FEV1/FVC
including HB-EGF and NGAL; and 9 analytes with DLCO
including HB-EGF, TGF-a, monocyte chemotactic protein-4
(MCP-4), Sortilin, Fibrinogen, sRAGE, tissue inhibitor of
metalloproteinase-1 (TIMP-1), VEGF and neutrophil-activating
peptide-2 (NAP-2) (Table S5; |correlation| .0.3, p,0.05, FDR
Systemic Biomarkers of COPD Disease Severity
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analyte that was consistently correlated with FEV1, FEV1/FVC
and DLCO, suggesting that it may be a general biomarker of lung
function decline in COPD. With the exception of HB-EGF and
TGF-a, analytes correlated with FEV1 were distinct from analytes
correlated with DLCO. Moreover, whereas serum levels of EN-
RAGE and sRAGE were both significantly different across COPD
disease severity groups (Table 2 and Figure 2), regression analysis
demonstrated that EN-RAGE correlated with FEV1 while sRAGE
correlated with DLCO. A post-hoc power analysis showed that the
Table 1. Characteristics of study cohort.
Total Non-Smokers Smokers GOLD I/II GOLD III/IV p
Patients (n) 185 (100%) 30 (16%) 15 (8%) 75 (41%) 65 (35%)
Demographics
Age in years 66.6 (0.5) 66.4 (1.1) 66.8 (1.7) 66.9 (0.7) 66.3 (0.7) 0.94
Males (n) 135 (73%) 21 (70%) 11 (73%) 54 (72%) 49 (75%) 0.95
Body Mass Index (BMI) 26.0 (0.4) 26.0 (0.8) 26.3 (0.8) 27.3 (0.5) 24.3 (0.7) ,0.001
Pack years 45.3 (2.2) 0.5 (0.2) 42.9 (5.3) 51.9 (2.9) 58.8 (3.1) ,0.001
Current smokers (n) 59 (32%) 0 (0%) 10 (67%) 30 (40%) 19 (29%) ,0.001
Systemic steroid use (n) 25 (14%) 0 (0%) 0 (0%) 5 (2.7%) 20 (11%) ,0.001
Theophylline use (n) 20 (11%) 0 (0%) 0 (0%) 2 (1.1%) 18 (9.7%) ,0.001
Metabolic Syndrome
Metabolic syndrome (n) 88 (48%) 13 (43%) 10 (67%) 44 (59%) 21 (32%) 0.006
Lung Function Parameters
Post bronchodilator FEV1% predicted 65.0 (43.0 – 96.0) 114.0 (108.5 2125.0) 100.0 (92.5 2 107.0) 75.0 (62.0 2 85.0) 36.0 (27.0 2 45.0) ,0.001
Post bronchodilator FEV1/FVC ratio 56.1 (43.8 2 72.8) 78.3 (75.8 2 80.9) 76.7 (74.8 2 78.7) 60.2 (51.2 2 65.8) 39.1 (34.0 2 46.0) ,0.001
DLCO % predicted (Hb corrected) 60.1 (39.5 2 74.8) 80.2 (74.8 2 89.1) 70.9 (61.5 2 81.6) 61.0 (51.7 2 73.0) 31.6 (24.8 2 42.1) ,0.001
Data are expressed as the number of subjects (% of subjects), mean (SEM) or median (Interquartile range) for lung function parameters. COPD subjects were grouped as
GOLD I/II (mild/moderate) and GOLD III/IV (severe/very severe).
doi:10.1371/journal.pone.0038629.t001
Figure 1. Overview of data analysis on COPD cohort.
doi:10.1371/journal.pone.0038629.g001
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associations with correlation .0.35 with power .0.6 at the a
=0.0005 level (Table S5). Analytes with stronger associations, such
as NGAL with FEV1/FVC ratio and HB-EGF and MCP-4 with
DLCO, were powered .0.8 at the a =0.0005 level.
Since univariate regression identified analytes that were
modestly correlated with lung function parameters (|r| =0.3 to
0.45), we next performed multivariate regression to determine if
the correlation with these same endpoints could be improved if a
set of analytes were used as predictors instead of individual
analytes. Multivariate analysis was performed using least angle
regression (LARS) with 5-fold nested cross-validation (CV). The
results are summarized in Table 3 with additional details in Table
S6 and Methods S1. Notably, the predictor set for DLCO (HB-
EGF, MCP-4, Fibrinogen, sRAGE and Sortilin) predicted a
substantial percentage of COPD subject variability in the test set
with a median value of 21%.
To better understand the functional association of the analytes
predictive of FEV1, FEV1/FVC and DLCO in regression
analyses, we asked if any of these proteins were enriched for
common functions or were associated with common cellular
pathways. Since proteins involved in similar functions and
processes are likely to be correlated, our approach was to cluster
the analytes selected in any one CV run from the multivariate
analysis by correlation, and determine whether members of these
clusters were enriched for association with specific lung function
parameters assessed in the regression analyses. A correlation
network (Figure 3) was constructed and three predominant clusters
of analytes were identified. As expected, analytes in the same
cluster were enriched for similar functions. For example, proteins
associated with neutrophil function (EN-RAGE, NGAL and
MPO) formed one cluster, while markers of systemic inflammation
(IL-6, Fibrinogen, CRP) formed another cluster. A third cluster
consisted of HB-EGF, TGF-a, platelet-derived growth factor
(PDGF) and placental growth factor (PLGF), growth factors
implicated in tissue injury and repair. When results from the
univariate analysis (Table S5) were overlaid onto the network, we
observed that members of the growth factor cluster (HB-EGF and
TGF-a) were significantly correlated with both DLCO and FEV1
related parameters. In contrast, members of the neutrophil
function cluster (EN-RAGE, NGAL, MPO) were uniformly
associated with FEV1-related parameters but not DLCO. Apart
from Fibrinogen, which was a member of the systemic inflamma-
tion cluster, analytes correlated with DLCO did not belong to any
particular functional cluster, suggesting that whereas decline in
FEV1 in COPD may be neutrophil associated, changes in DLCO
may not be associated with any one specific cellular pathway or
mechanism.
Analysis III: Regression Analysis in COPD Patients with
and Without Metabolic Syndrome
Next, we asked if biomarker associations with lung function
parameters could be affected by the presence or absence of
coexisting metabolic syndrome. To assess this, we first confirmed
that COPD subjects with and without metabolic syndrome were
well-matched and did not display any significant differences with
respect to demographic covariates (Table S7). Analysis was
performed on COPD patients not on theophylline and/or oral
systemic steroids. COPD patients were subdivided based on the
presence (n =55) or absence (n =47) of metabolic syndrome and
univariate analysis was performed on each subpopulation (see
Figure 1). MCP-4 was significantly correlated with DLCO in
patients with metabolic syndrome, while Fibrinogen and HB-EGF
were significantly associated with DLCO in patients without
metabolic syndrome (Table 4). NGAL and MPO, both neutrophil
associated markers, were also significantly associated with FEV1/
FVC ratio in patients without metabolic syndrome. While the p
value for interaction with metabolic syndrome was not significant
at the p,0.05 level for any of these analytes, interaction p values
for MPO and Fibrinogen were 0.09 and 0.08, respectively
(Table 4). Both MPO and Fibrinogen were strongly negatively
correlated with increasing FEV1/FVC (r = 20.61) and DLCO (r
= 20.52), respectively, in patients without metabolic syndrome
(Table 4 and Figure 4), suggesting that neutrophilia and systemic
inflammation may be more strongly associated with disease
severity in this subgroup of COPD patients. Multivariate analysis
was attempted on COPD patients with and without metabolic
syndrome, however, the sample size in these subgroups was too
small to reliably perform cross-validation.
Discussion
In the present study, we performed a cross-sectional
biomarker evaluation of samples from a COPD cohort, with
the aim of using multiplex protein profiling to identify systemic
biomarker changes associated with measures of disease severity
in all COPD patients as a group, as well as in COPD patients
with or without metabolic syndrome. Looking at all subjects, we
identified 7 proteins with significantly different levels when
comparing mild/moderate and severe/very severe COPD
Table 2. Protein analyte differences between COPD and control disease severity groups.
Analyte Non-Smokers (N =30) Smokers (N =15) GOLD I/II (N =75) GOLD III/IV (N =65) P (FDR)
EN-RAGE 13.1 (7.7 2 17.4) 20.0 (13.0 2 27.6) 19.5 (12.5 2 29.2) 35.5 (20.0 2 53.5) 0.001
TGF2a* 0.051 (0.045 2 0.055) 0.068 (0.053 2 0.075) 0.048 (0.042 2 0.060) 0.058 (0.045 2 0.073) 0.003
sRAGE 4.2 (3.3 2 5.2) 3.2 (2.4 2 5.0) 2.7 (1.5 2 3.5) 2.2 (1.5 2 3.0) 0.003
Fibrinogen 0.37 (0.34 2 0.42) 0.46 (0.44 2 0.49) 0.43 (0.37 2 0.47) 0.46 (0.42 2 0.53) 0.004
NGAL* 309.2 (258.6 2 354.2) 273.7 (233.2 2 338.1) 269.0 (211.0 2 340.2) 351.5 (272.5 2 441.5) 0.005
MPO* 414.5 (352.5 2 457.9) 382.0 (284.0 2 622.0) 379.0 (268.0 2 581.2) 553.0 (345.0 2 806.0) 0.02
HB-EGF* 0.18 (0.15 2 0.24) 0.23 (0.17 2 0.27) 0.18 (0.12 2 0.24) 0.27 (0.17 2 0.32) 0.02
Data are expressed as median (interquartile range) in ng/ml for individual analytes, except for Fibrinogen which is in mg/dl.
All analyte data shown are from profiling on the RBM Luminex platform, except for Fibrinogen which was tested at Hospital Grosshansdorf. COPD subjects were
grouped as GOLD I/II (mild/moderate) and GOLD III/IV (severe/very severe). ANOVA was used for group-wise comparisons, except for analytes noted with *, which did
not follow a normal distribution and a non-parametric Kruskal Wallis test was used.
doi:10.1371/journal.pone.0038629.t002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38629Figure 2. Increased serum EN-RAGE and decreased serum sRAGE are associated with COPD disease severity. Log2-transformed levels
of EN-RAGE (A, C) and sRAGE (B, D) (ng/ml) for each subject are plotted with box-whisker plots illustrating median, 25
th and 75
th percentiles for non-
smoking controls (NS), smoking controls (S), GOLD I and II (mild/moderate COPD) and GOLD III and IV (severe/very severe COPD) groups (A, B) and
former and current smoker groups (C, D). Whiskers extend to data outside 1.5 times interquartile range.
doi:10.1371/journal.pone.0038629.g002
Table 3. Multivariate analysis of protein analyte data for COPD subjects.
Lung Function Parameter Spearman Correlation
Adjusted R
Squared Analytes
FEV1%predicted 0.48 0.03 HB-EGF, EN-RAGE, MIP-1b
FEV1/FVC ratio 0.47 0.14 NGAL, HB-EGF, GST-a, MIP-1b
DLCO %predicted 0.43 0.21 HB-EBF, MCP-4, Fibrinogen, sRAGE, Sortilin
Spearman correlation and adjusted R squared values were computed using test set samples, in a 5-fold nested cross-validation scheme, averaged over 10 random seeds.
R squared values were adjusted for the number of predictor terms in the model.
doi:10.1371/journal.pone.0038629.t003
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proteins significantly correlated with at least one of the following
lung function parameters in a univariate analysis: FEV1, FEV1/
FVC and DLCO. In particular, using multivariate analysis we
identified a 5-analyte predictor set comprised of HB-EGF,
MCP-4, Fibrinogen, sRAGE and Sortilin that could explain up
to 21% of subject variability in DLCO. When subjects were
sub-grouped based on the presence of coexisting metabolic
syndrome, we observed that MPO and Fibrinogen were strongly
negatively associated with FEV1/FVC and DLCO, respectively,
in patients without metabolic syndrome but not in patients with
metabolic syndrome.
Our findings are consistent with previous biomarker studies in
COPD, and extend these by relating known and novel markers to
disease severity. For example, we demonstrated that Fibrinogen
levels increase with COPD severity, consistent with its role as a
marker of chronic inflammation and association with lung
function decline in COPD [28,29,30]. MPO and NGAL, both
Figure 3. Correlation network illustrating functional co-clustering of analytes associated with FEV1, FEV1/FVC and DLCO. Analytes
are plotted in a network using Cytoscape [83] where nodes represent analytes and edges represent significant correlations (r .0.4, p,0.05, corrected
for multiple testing). Analytes are colored according to whether they were associated with FEV1 related parameters (green), DLCO (red) or both DLCO
and FEV1 related parameters (orange) in univariate regression. Node size is proportional to the number of lung function parameters that showed
significant association with a given analyte. Clusters of co-expressed analytes with similar function are highlighted by dotted regions in the grapha s
neutrophil function (orange), systemic inflammation (blue) and growth factor pathways (grey).
doi:10.1371/journal.pone.0038629.g003
Table 4. Univariate regression analysis of protein analytes versus lung function parameters in COPD subjects with and without
metabolic syndrome.
With Metabolic Syndrome (n =55) Without Metabolic Syndrome (n =47)
Lung Function Parameter/
Analyte Spearman Correlation p (FDR) Spearman Correlation p (FDR) Interaction p
FEV1/FVC ratio
MPO 20.15 0.96 20.61 0.023 0.09
NGAL 20.35 0.25 20.54 0.023 0.65
DLCO % predicted
Fibrinogen 20.25 0.47 20.52 0.005 0.08
HB-EGF 20.44 0.13 20.45 0.027 0.55
MCP-4 20.52 0.03 20.28 0.342 0.29
Significance (p values) and effect sizes (spearman correlation) are listed for biomarker associations with lung function parameters. Interaction p values indicate
significance of differences in biomarker associations with lung function parameters, between metabolic syndrome and non- metabolic syndrome groups.
doi:10.1371/journal.pone.0038629.t004
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severity and NGAL was correlated with FEV1/FVC by univariate
and multivariate regression, consistent with the role of neutrophils
in COPD pathogenesis [31] and recent reports that sputum
neutrophilia increases with GOLD stage and is weakly associated
with FEV1 [32]. Apart from its ability to reflect neutrophil
activation, NGAL also functions as an antimicrobial and matrix
degrading protein, the latter by binding to and inhibiting the
inactivation of MMP-9 [14], suggesting a broader role for this
marker in COPD. Indeed, NGAL has been proposed as a
biomarker capable of predicting tissue injury in a number of acute
and chronic inflammatory conditions such as vascular and renal
disease [33].
One of the most striking findings in our study was the
dichotomy of EN-RAGE and sRAGE association with COPD
disease severity. When COPD patients were compared to smokers
and non-smoking controls, EN-RAGE levels were significantly
elevated in severe/very severe COPD patients, while sRAGE
levels were significantly decreased with increasing disease severity.
Univariate and multivariate regression further demonstrated that
while EN-RAGE strongly associated with FEV1 and FEV1/FVC,
sRAGE associated with DLCO, suggesting that these two
members of the RAGE signaling pathway are differentially
Figure 4. Association of MPO with FEV1/FVC and Fibrinogen with DLCO in COPD patients with and without metabolic syndrome.
Log2-transformed levels of MPO (A, C) and Fibrinogen (B, D) (ng/ml for MPO and mg/dl for Fibrinogen) are plotted against covariate adjusted values
for FEV1/FVC and DLCO, respectively in COPD patients with (A, B) and without (C, D) metabolic syndrome (r values indicate spearman correlation,
covariates include age, sex, BMI, pack years and smoking status).
doi:10.1371/journal.pone.0038629.g004
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of lung destruction and emphysema.
RAGE is a multi-ligand receptor for diverse ligands such as
advanced glycation end products (AGEs), S100 proteins (including
S100A12/EN-RAGE) and high mobility group box 1 (HMGB1),
and ligand-mediated activation of RAGE leads to inflammation
and tissue injury [34,35,36,37]. EN-RAGE is predominantly
expressed by granulocytes and monocytes, and has a broad role in
inflammatory responses [38,39,40,41,42,43]. sRAGE is a soluble
extracellular decoy receptor for RAGE that protects against
inflammation and tissue injury [44,45,46]. In the lung, alveolar
type I (AT-I) epithelial cells express high basal levels of RAGE [36]
where it has been suggested to play an additional protective role by
enhancing the interaction of AT-I cells with the basal lamina to
promote effective gas exchange and alveolar stability [47]. In
response to inflammation and lung injury [48,49] sRAGE can be
released from the alveolar epithelium via MMP-3 and MMP-13
dependent cleavage. RAGE ligands can also induce the expression
of MMP-3 and MMP-13 [50]. Our observation of increased EN-
RAGE and decreased sRAGE, with increased COPD severity
suggests that the loss of sRAGE might be a consequence of
alveolar epithelial cell loss due to MMP-induced matrix degrada-
tion and emphysematous lung destruction in severe COPD. The
positive correlation on regression between decreased sRAGE and
decreasing DLCO - a surrogate measure of emphysema - is
consistent with this hypothesis. On the other hand, the correlation
of increased EN-RAGE with a decline in FEV1 likely reflects high
levels of underlying systemic inflammation in these patients,
consistent with previous associations of CRP, IL-6 and Fibrinogen
with COPD disease severity [7,9,29].
These findings support and extend an increasing number of
studies demonstrating dysregulation of the RAGE pathway in
chronic inflammatory disorders including arthritis, diabetes, and
cardiovascular, peripheral vascular and respiratory diseases
[35,40,48,51,52,53]. In COPD, HMGB1, AGEs and RAGE have
been shown to be overexpressed in the airways of COPD patients
[54,55]. Smith et al. [56] also recently showed that plasma sRAGE
was reduced in patients with stable COPD and correlated with
FEV1. A strong negative association of sRAGE with airway
neutrophilia was also recently reported for asthma and COPD
[57]. Several large genome-wide association studies also reported
that single nucleotide polymorphisms in the AGER gene that
codes for RAGE were associated with a reduced FEV1/FVC ratio
indicative of airflow obstruction [58]. Taken together, these
findings suggest that activation of the RAGE pathway may
represent a nonspecific pathway of sustained inflammation and
lung parenchymal tissue injury in COPD.
Another observation from this study was the strong association
between HB-EGF and TGF-a with multiple lung function
parameters in COPD. HB-EGF was the only analyte significantly
associated with FEV1, FEV1/FVC and DLCO, suggesting that it
may be a general marker of COPD disease severity. To our
knowledge this is the first report of increased serum HB-EGF
being associated with COPD disease severity. HB-EGF and TGF-
a are ligands for the epidermal growth factor receptor (EGFR) that
are synthesized as transmembrane precursors and subsequently
released by proteolytic cleavage as biologically active mature
proteins [59,60]. HB-EGF and TGF-a have been shown to
participate in epithelial repair processes and airway remodeling
both in vitro and in vivo in models of lung disease [61,62,63,64]. In
particular, TGF-a has been associated with altered lung remod-
eling in human diseases such as chronic bronchopulmonary
dysplasia and idiopathic pulmonary fibrosis (IPF) [65,66,67].
Increased protease activity and matrix breakdown during emphy-
sema pathogenesis could increase HB-EGF and TGF-a levels in
serum and account for the association of these proteins with lung
function decline as measured by FEV1 and DLCO. EGFR and its
ligands are normally weakly expressed in healthy airway epithe-
lium but are upregulated in bronchial tissue of COPD patients by
exposure to oxidative stress [68]. EGFR pathway activation can
also be induced by exposure to oxidative stress, activated
neutrophil supernatant or cigarette smoke [69,70]. In turn, EGFR
pathway activation can induce mucin production in airway
epithelial cells and contribute to the mucus hyperproduction
phenotype seen in COPD [69,71]. These findings suggest a role
for neutrophils in EGFR pathway activation that could explain the
association of TGF-a and HB-EGF with disease severity and
FEV1 in the current study. These findings also support the
emerging idea that targeting lung repair mechanisms may be an
approach for therapeutic intervention in COPD [72].
Comparing the results of the group-wise and regression analyses
(i.e. analysis I and II), it is interesting that while both analyses
identified similar analytes, the overlap between identified analytes
was not 100%. This could be due to a number of reasons. First,
subjects were divided into discrete groups in analysis I based on
GOLD stage, which used specified cutoffs primarily based on
FEV1, whereas in analysis II, FEV1 was used as a continuous
variable for univariate regression with biomarker levels. Second,
the power of group-wise tests (ANOVA or Kruskal-Wallis) to
detect significant differences is sensitive to the number of samples
in each group, whereas significance in univariate regression is
dependent on the total number of samples. Third, only COPD
patients were considered in univariate regression, whereas COPD
patients were compared against non-COPD subjects in the group-
wise analysis. Despite these differences, both methods identified
analytes associated with epithelial repair (HB-EGF and TGF-a)
and neutrophil function (EN-RAGE, MPO and NGAL) as
significant, the latter being consistent with the hypothesis that
neutrophil levels are strongly associated with the development of
COPD, increasing COPD severity and FEV1 decline.
Using multivariate methods, we identified HB-EGF, MCP-4,
Fibrinogen, sRAGE and Sortilin as a 5 analyte predictor set that
could predict approximately 20% of test set patient variability in
DLCO (adjusted R squared). This is significant given that few
surrogate markers of DLCO have been reported in the COPD
literature to date, and also because this evaluation of predictability
was obtained on the test set in a cross-validation framework. These
markers are associated with processes such as epithelial injury
(sRAGE) and tissue repair (HB-EGF), consistent with the concept
that DLCO is a surrogate marker of emphysema severity.
Interestingly, markers of neutrophil function (i.e. NGAL and
EN-RAGE) were associated with FEV1-related parameters but not
DLCO.
Metabolic syndrome has been observed to be a frequent
comorbidity in patients with COPD [73]. Patients with metabolic
syndrome often present with higher levels of systemic inflamma-
tory markers such as CRP, TNF-a, Fibrinogen and IL-6 [74], and
these markers are also increased in the blood of COPD patients
[7,10]. In a prior study in our patient cohort [21], Watz et al.
reported that the presence of metabolic syndrome was an
independent predictor of IL-6 and hsCRP levels in COPD
patients, with the levels of these markers displaying the same
increasing trend with disease severity in COPD patients with and
without metabolic syndrome, but being consistently higher in
patients with coexisting metabolic syndrome. In the current study,
CRP and IL-6 levels measured three years later in the same cohort
were also higher in patients with metabolic syndrome but did not
pass cutoffs for statistical significance (p,0.08 for CRP and
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patients with metabolic syndrome face an added systemic
inflammatory burden compared to COPD patients without
metabolic syndrome, which could predispose them to worsened
health outcomes and other comorbid diseases [23].
The independent contribution of metabolic syndrome to the
increase in systemic levels of inflammatory markers may present
an additional complication for biomarker studies. In our study,
Fibrinogen and MPO displayed different associations with lung
function parameters in COPD patients with and without
coexisting metabolic syndrome, with Fibrinogen and MPO levels
being significantly negatively correlated with DLCO and FEV1,
respectively, only in patients without metabolic syndrome.
Interestingly, both Fibrinogen and MPO were associated with
DLCO and FEV1 when all patients were considered regardless of
metabolic syndrome, suggesting that in the general population
these associations may be driven by stronger associations within
the non-metabolic syndrome subpopulation. Based on these
findings, it may be useful to consider the presence of metabolic
syndrome in future biomarker studies investigating the underlying
molecular processes driving COPD pathogenesis.
There are a number of limitations to the current study that
should be considered. This study was performed as a cross-
sectional evaluation and therefore the associations of biomarkers
with lung function parameters are correlative and not predictive.
Furthermore, sample sizes across disease severity groups were
unbalanced which affected the power to detect associations with
modest effect size. Despite these limitations, we were able to
distinguish significant associations of known and novel systemic
biomarkers with multiple lung function parameters. This was likely
facilitated by the fact that our subjects were recruited from a single
center. Independent confirmation in larger cohorts across multiple
centers, or longitudinal sampling studies will be needed to validate
the novelty of biomarker associations identified in the current
study. Nevertheless, our observations support the idea that distinct
biological processes such as systemic inflammation, neutrophil
activation and epithelial tissue injury/repair are associated with
COPD disease severity. These pathways may therefore be linked
to COPD pathophysiology and have the potential for identifica-
tion of novel targets and biomarkers to address the unmet medical
needs in these patients.
Materials and Methods
Ethics Statement
This study was performed in conformity with requirements
approved by the institutional review board of Hoffmann-La Roche
Inc. This study was approved by the local ethics committee of
Schleswig-Holstein and all participants gave written informed
consent.
Subjects in Overall Study Cohort
Subjects in this study were recruited as part of an ongoing
prospective observational study at the Pulmonary Research
Institute at Hospital Grosshansdorf, Germany to examine the role
of extrapulmonary effects of COPD including systemic inflamma-
tion and metabolic syndrome on disease severity and disease
progression [21,22,24,25,26,27]. The present study is a cross-
sectional analysis of the follow up visit with this COPD cohort in
2008/2009, and comprises 30 healthy non-smokers, 15 smoking
controls with chronic bronchitis (GOLD 0 in former GOLD
classification scheme), and 140 patients with stable COPD (GOLD
stage I-IV). Cross-sectional analyses of the baseline visit and
survival analysis have been published previously [21,22,24,25].
Clinical Characteristics
Post-bronchodilator spirometry (performed 15 minutes after
administration of 400 mg salbutamol) and DLCO were measured
according to current guidelines using established reference values
[75,76,77,78]. The metabolic syndrome was assessed according to
the criteria of the International Diabetes Federation as follows:
central obesity (waist circumference $94 cm for men and $80 cm
for women) plus any two of the following four factors: 1)
triglycerides $150 mg/dL or specific treatment for this lipid
abnormality; 2) high-density lipoprotein cholesterol ,40 mg/dL
in males and ,50 mg/dL in females, or specific treatment for this
lipid abnormality; 3) systolic blood pressure $130 mmHg or
diastolic blood pressure $85 mmHg, or treatment of previously
diagnosed hypertension; 4) fasting plasma glucose $100 mg/dL or
previously diagnosed type 2 diabetes [79].
Sample Collection and Analysis
Serum and plasma were collected at the time of the study visit at
Hospital Grosshansdorf. Blood was collected separately into
Sarstedt monovette syringes (Sarstedt Inc., Newton, NC) contain-
ing aluminum silica as the coagulant for serum collection, or
citrate as the anti-coagulant for plasma collection. For serum
collection, blood was allowed to stand at room temperature for
30 min and then centrifuged at 4uC for 10 minutes at 3000 rpm.
Serum was removed, aliquoted and stored at 220uC within 1 hour
of blood sampling. Plasma samples were used for the measurement
of Fibrinogen levels according to the modified method of Clauss
[80]. Serum levels of 142 protein analytes were measured using
two multiplex platforms: Luminex multi-analyte profiling at Rules
Based Medicine (RBM, Austin, TX) and Searchlight at Aushon
Biosystems (Bellerica, MA). The RBM panel comprised 126
proteins and the Aushon Searchlight panel comprised 27 proteins.
The analytes run on the Aushon platform were selected to
complement the RBM panel and included analytes for which
assays were not available with RBM (e.g. CC-16). Eleven analytes
were evaluated on both platforms (CRP, NT-Pro-BNP, sRAGE,
EN-RAGE, IL-6, sIL-6R, IL-10, IL-13, IL-18, PARC, Throm-
bopoietin), however, in these cases, only data from RBM was used
in the biomarker analysis. Table S1 lists all 142 analytes tested and
the associated multiplex platform.
Analysis I: Group-wise Comparisons Using all Subjects
The goal of this analysis was to determine if biomarker levels
differed across non-smoking control, smoking control, mild/
moderate COPD (GOLD I, II) and severe/very severe COPD
(GOLD III, IV) subject groups. Subject inclusion/exclusion
criteria: All 185 subjects were included in this analysis. Subject
numbers in each group are as follows: non-smoking controls (n
=30), smoking controls with chronic bronchitis (n =15), mild/
moderate COPD (GOLD I/II, n= 75), severe/very severe COPD
(GOLD III/IV, n =65). Biomarker inclusion/exclusion criteria:
Of the original set of 142 analytes that were measured (see Table
S1), 113 were considered for analysis, while 14 analytes were
eliminated due to too many missing values (missing in .80% of all
subjects) and 15 analytes were eliminated that had fewer than 10
subjects in each group with valid values. Full details of the group-
wise analysis can be found in Figure S1.
Statistical analysis: The fraction of missing data samples was
compared across disease severity groups to identify non-random
trends in missing data distribution (Table S8). IL-6, Eotaxin-3 and
IL-1Ra showed non-random distributions. For example, IL-6
levels were below the limit of detection for most non-smoking
control subjects, while IL-6 was present at detectable levels in
smoking, mild/moderate and severe/very severe COPD subjects.
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however, following log transformation the distributions for 74 of
the 113 analytes remained insufficiently normal for application of
parametric methods. A non-parametric test (Kruskal-Wallis) was
used for these 74 analytes, while ANOVA was used for the 39
normally-distributed analytes. Protein analyte levels were adjusted
for age, sex, BMI, pack years and current smoking status. Analytes
with p,0.05 (FDR corrected for multiple testing) were considered
significant. Table S1 lists all 142 analytes, whether they were
normally distributed, the number of missing values, the type of test
performed, and whether a significant association was discovered.
R (version 2.13.2) was used for analysis. G*Power 3.1 was used for
power analysis [81,82].
Analysis II: Regression Analyses in COPD Patients Only
The goal of this analysis was to identify systemic biomarkers
associated with lung function parameters within COPD patients
only. Subject inclusion/exclusion criteria: Of the 140 COPD
patients in this cohort, 38 patients on theophylline and/or oral
systemic steroids were removed to avoid potential confounding
effects of pre-medication. Analysis was thus performed on the 102
remaining COPD patients. Biomarker inclusion/exclusion crite-
ria: The same set of 113 analytes evaluated in Analysis I was used
for regression analysis.
Statistical analysis: In univariate regression, protein analytes
significantly associated with lung function parameters were
identified by ANCOVA with lung function parameter and
serum/plasma concentration level as dependent and independent
variables. Age, gender, body mass index (BMI), pack years and
smoking status were included in the model as covariates. Lung
function parameters tested were post-bronchodilation FEV1%pre-
dicted (FEV1), post-bronchodilation FEV1/FVC ratio (FEV1/
FVC) and DLCO %predicted (Hb-corrected). Analytes were
considered significantly correlated if the absolute value of the
Spearman correlation coefficient .0.3 and p,0.05, FDR
corrected for multiple testing. Multivariate analysis was also
performed to identify a set of analytes that when tested in
combination, could explain a significant percentage of the
variability of lung function parameter measures across COPD
subjects. A least angle regression (LARS) procedure and five-fold,
stratified, nested cross-validation (CV) was used to assess the
predictive performance of the resulting LARS model (details in
Methods S1). Analytes selected in .50% CV runs were used as a
final multivariate predictor set for each lung function parameter. R
(version 2.13.2) was used for analysis. G*Power 3.1 was used for
power analysis [81,82]. For the correlation network analysis, a
network was constructed using Cytoscape [83] where an edge
linking a pair of nodes represented analytes with a pairwise
correlation .0.4. Analytes were colored green, red or orange if
they were significantly correlated with FEV1 related parameters
(FEV1%predicted, FEV1/FVC), DLCO or both, respectively.
Node sizes in the network were proportionate to the number of
lung function parameters that showed significance for any given
analyte.
Analysis III: Regression Analyses in COPD Patients with
and without Metabolic Syndrome
The goal of this analysis was to determine if the biomarker
associations with lung function parameters differed between
COPD patients with and without metabolic syndrome. Subject
inclusion/exclusion criteria: Similar to analysis II, analysis III was
performed on 102 COPD patients not taking theophylline and/or
oral systemic steroids. This population was divided into 2
subpopulations: 55 COPD patients with metabolic syndrome
and 47 patients without metabolic syndrome. Biomarker inclu-
sion/exclusion criteria: The same set of 113 analytes used in
Analysis II was used for this analysis. Statistical analysis: The same
univariate regression methods as Analysis II were used to assess
biomarker associations with lung function parameters in the
metabolic syndrome and non-metabolic syndrome subpopulations.
Supporting Information
Figure S1 Analysis workflow for analysis I: group-wise
comparisons.
(TIFF)
Table S1 Full table listing number of missing values,
median (IQR) in each group, test employed (parametric
vs. non-parametric) and group-wise comparison signif-
icance for all 142 analytes.
(XLS)
Table S2 Post-hoc pairwise comparisons for protein
analytes with significant differences across disease
severity groups. Analytes shown above had significant p values
(p,0.05) using ANOVA or Kruskal-Wallis (*) test in group-wise
comparison after correction for multiple testing with FDR
(Table 2). Pairwise comparisons were computed using Tukey
HSD test. NS: Non-smoking controls, S: Smoking controls,
GOLD I/II: mild/moderate COPD, GOLD III/IV: severe/very
severe COPD. Fold changes highlighted in bold represent pairwise
comparisons driving significance in overall group comparison.
(DOC)
Table S3 Post-hoc pairwise comparisons for protein
analytes with significant differences across FEV1 quar-
tile groups. Analytes shown above had significant p value
(p,0.05) using ANOVA or Kruskal-Wallis (*) test after correction
for multiple testing with FDR. Pairwise comparisons were
computed using Tukey HSD test. Subjects were grouped by
FEV1 quartile: 1st: 0–25%, 2nd: 25250%,3rd: 50–75%, 4th: 75–
100%.
(DOC)
Table S4 Post-hoc power analysis for analysis I: group-
wise comparisons. Analyte values were adjusted for age,
gender, BMI, pack years and current smoking status. NS: Non-
smoking controls, S: Smoking controls, GOLD I/II: mild/
moderate COPD, GOLD III/IV: severe/very severe COPD.
Power was calculated for two cases: i) significance at the p,0.05
level without multiple testing correction, and ii) significance at the
p,0.05, correcting for multiple testing using the Bonferroni
method with 100 analytes. Analysis was performed assuming a
one-way ANOVA model. Bold values indicate analytes with power
.0.6 at the a =0.0005 level.
(DOC)
Table S5 Univariate regression and post-hoc power
analysis of protein analytes versus lung function pa-
rameters. Power was calculated for two cases: i) significance at
the p,0.05 level without multiple testing correction, and ii)
significance at the p,0.05, correcting for multiple testing using the
Bonferroni method with 100 analytes. Bold values indicate
analytes with power .0.6 at the a =0.0005 level.
(DOC)
Table S6 Multivariate analysis of protein analyte data
for COPD subjects. All analytes, unless indicated otherwise,
were profiled using the RBM Luminex platform. *Profiled using
the Aushon Searchlight platform; **Profiled at Hospital Gros-
shansdorf. Abbreviations in addition to those in text of manuscript:
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acid phosphatase; GST-a: glutathione S-transferase alpha; ENA-
78: epithelial neutrophil-activating peptide-78. The numbers in
parentheses indicate the frequency with which this particular
analyte was selected in the cross-validation runs of the multivariate
analysis. The analytes highlighted in bold are those selected in
.50% of the CV runs and represent the analytes used as a final
multivariate predictor set for the particular lung function
parameter.
(DOC)
Table S7 Demographics for COPD subjects with and without
metabolic syndrome. Data are expressed as the number of subjects
(% of subjects), mean (SEM) or median (Interquartile range) for
lung function parameters
(DOC)
Table S8 Distribution of samples with missing data
values across disease severity groups. Data are reported as
n (fraction of samples with missing data compared to all samples in
disease severity group). C.V indicates coefficient of variation =
standard deviation of missing data fraction/mean missing data
fraction across severity groups. NS: Non-smoking controls, S:
Smoking controls, GOLD I/II: mild/moderate COPD, GOLD
III/IV: severe/very severe COPD.
(DOC)
Methods S1 Details of serum analyte analysis, multi-
variate model learning and performance evaluation.
(DOC)
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